HealthCare Global Q4 Review - Growth Momentum To Continue: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
HealthCare Global Enterprises Ltd.’s Q4 FY21 performance was broadly inline with our estimates driven by continued sequential recovery in the oncology hospital segment revenue that grew 8.8% QoQ.
However, higher than expected costs suppressed Ebitda margin to 13.2% (our estimate: 14.5%).
We expect the recovery trend to continue and normalcy to be achieved by H2 FY22E.
Recent capital infusion has removed the key overhang of high leverage with repayment of debt from the fund raising exercise.
We remain positive on the stock as the company is poised to grow positively hereon and strengthening of balance sheet with no major capex plan in near term.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.